Description: Trevena, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing therapeutics for G protein coupled receptors. Its products include TRV027 that has completed Phase 2a clinical trials for the treatment of acute heart failure; TRV130, a small molecule G protein biased ligand at the ยต-opioid receptor has completed Phase 1b clinical trials to treat moderate to severe acute pain intravenously; TRV734 that is in preclinical studies as a orally administered treatment of moderate to severe acute and chronic pain; and d-opioid receptor G protein biased ligand therapeutics for the treatment of central nervous system disorders. The company was formerly known as Parallax Therapeutics, Inc. and changed its name to Trevena, Inc. in January 2008. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.
Home Page: www.trevena.com
TRVN Technical Analysis
955 Chesterbrook Boulevard
Chesterbrook,
PA
19087
United States
Phone:
610 354 8840
Officers
| Name | Title |
|---|---|
| Ms. Carrie L. Bourdow | Pres, CEO & Director |
| Mr. Barry Shin | Sr. VP & CFO |
| Dr. Mark A. Demitrack | Sr. VP & Chief Medical Officer |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board |
| Mr. Joel Solomon | VP, Head of Legal, Chief Compliance Officer & Corp. Sec. |
| Mr. Michael Catalano | VP of Marketing |
| Mr. Robert T. Yoder | Sr. VP, Chief Bus. Officer & Head of Commercial Operations |
| Ms. Patricia M. Drake | Sr. VP & Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5689 |
| Price-to-Sales TTM: | 106.0323 |
| IPO Date: | 2014-01-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |